持续动静脉血液透析滤过过程中万古霉素的清除率。

Clearance of vancomycin during continuous arteriovenous hemodiafiltration.

作者信息

Bellomo R, Ernest D, Parkin G, Boyce N

机构信息

Department of Medicine, Monash Medical Centre, Prince Henry's Hospital, Melbourne, Australia.

出版信息

Crit Care Med. 1990 Feb;18(2):181-3. doi: 10.1097/00003246-199002000-00011.

DOI:10.1097/00003246-199002000-00011

PMID:2298011

Abstract

The clearance of vancomycin during therapy with continuous arteriovenous hemodiafiltration (CAVHD) has been measured in vivo. Vancomycin clearances (n = 16) were 0.636 +/- 0.269 L/h (10.5 +/- 4.46 ml/min). Effective drug clearances were proportional to ultrafiltrate volumes, reflecting convective clearance. Clearances of vancomycin on CAVHD were approximately twice the values seen with continuous arteriovenous hemofiltration. These data allow construction of a dosing schedule for vancomycin therapy in patients receiving renal support via CAVHD.

摘要

已在体内测量了持续动静脉血液透析滤过（CAVHD）治疗期间万古霉素的清除率。万古霉素清除率（n = 16）为0.636±0.269 L/h（10.5±4.46 ml/min）。有效药物清除率与超滤量成正比，反映了对流清除。CAVHD时万古霉素的清除率约为持续动静脉血液滤过时所见值的两倍。这些数据有助于制定通过CAVHD接受肾脏支持的患者万古霉素治疗的给药方案。